TY  - JOUR
AU  - Vela, Paloma
AU  - Sanchez-Piedra, Carlos
AU  - Perez-Garcia, Carolina
AU  - Castro-Villegas, María C
AU  - Freire, Mercedes
AU  - Mateo, Lourdes
AU  - Díaz-Torné, Cesar
AU  - Bohorquez, Cristina
AU  - Blanco-Madrigal, Juan M
AU  - Ros-Vilamajo, Inmaculada
AU  - Gómez, Silvia
AU  - Caño, Rocio
AU  - Sánchez-Alonso, Fernando
AU  - Díaz-González, Federico
AU  - Gómez-Reino, Juan J
PY  - 2020
DO  - 10.1186/s13075-020-02231-x
UR  - http://hdl.handle.net/10668/15740
T2  - Arthritis research & therapy
AB  - To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). All patients in the...
LA  - en
KW  - Ankylosing spondylitis
KW  - Biologics
KW  - Elderly-onset rheumatoid arthritis
KW  - Psoriatic arthritis
KW  - Rheumatoid arthritis
KW  - Adult
KW  - Aged
KW  - Antirheumatic Agents
KW  - Arthritis, Psoriatic
KW  - Arthritis, Rheumatoid
KW  - Biological Products
KW  - Female
KW  - Humans
KW  - Male
KW  - Methotrexate
KW  - Middle Aged
KW  - Spondylitis, Ankylosing
KW  - Young Adult
TI  - Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register.
TY  - research article
VL  - 22
ER  -